FUSED PYRAZOLE DERIVATIVE HAVING AUTOTAXIN INHIBITORY ACTIVITY
申请人:The University of Tokyo
公开号:EP3112369A1
公开(公告)日:2017-01-04
The present invention provides a compound of formula (I), wherein R1, R2, R3, R4a, R4b, R5a and R5b are as defined in the description, which has an autotaxin inhibitory activity, a pharmaceutical composition comprising the compound as an active ingredient, and a method of prevention or treatment of a disease involving autotaxin, which is characterized by administering the compound.
[EN] HETEROCYCLIC FXR MODULATORS<br/>[FR] MODULATEURS HÉTÉROCYCLIQUES DE FXR
申请人:HEPAGENE THERAPEUTICS INC
公开号:WO2018075207A1
公开(公告)日:2018-04-26
The present technology is directed to compounds of formula (I), compositions, and methods related to modulation of FXR. In particular, the present compounds and compositions may be used to treat FXR-mediated disorders and conditions, including, e.g., liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, and atherosclerosis, and renal disease.
[EN] NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS<br/>[FR] COMPOSÉS BICYCLIQUES FUSIONNÉS CONTENANT DE L'AZOTE EN TANT QU'INHIBITEURS DE PROTÉASE 1 DE TRAITEMENT SPÉCIFIQUE DE L'UBIQUITINE
申请人:KSQ THERAPEUTICS INC
公开号:WO2021247606A1
公开(公告)日:2021-12-09
The present disclosure provides compounds having Formula (I): (I) and the pharmaceutically acceptable salts and solvates thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R6, R6', R7, and R7' are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to inhibit a USP1 protein and/or to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Compounds of the present disclosure are especially useful for treating cancer.
[EN] HETEROCYCLIC GLP-1 AGONISTS<br/>[FR] AGONISTES HÉTÉROCYCLIQUES DE GLP-1
申请人:GASHERBRUM BIO INC
公开号:WO2022052958A1
公开(公告)日:2022-03-17
This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
Two Distinct Mechanisms of Inhibition of LpxA Acyltransferase Essential for Lipopolysaccharide Biosynthesis
作者:Wooseok Han、Xiaolei Ma、Carl J. Balibar、Christopher M. Baxter Rath、Bret Benton、Alun Bermingham、Fergal Casey、Barbara Chie-Leon、Min-Kyu Cho、Andreas O. Frank、Alexandra Frommlet、Chi-Min Ho、Patrick S. Lee、Min Li、Andreas Lingel、Sylvia Ma、Hanne Merritt、Elizabeth Ornelas、Gianfranco De Pascale、Ramadevi Prathapam、Katherine R. Prosen、Dita Rasper、Alexey Ruzin、William S. Sawyer、Jacob Shaul、Xiaoyu Shen、Steven Shia、Micah Steffek、Sharadha Subramanian、Jason Vo、Feng Wang、Charles Wartchow、Tsuyoshi Uehara
DOI:10.1021/jacs.9b13530
日期:2020.3.4
mechanisms of LpxA inhibition; compound 1 is a substrate-competitiveinhibitor targeting apo LpxA, and compound 2 is an uncompetitive inhibitor targeting the LpxA/product complex. Compound 2 exhibited more favorable biological and physicochemical properties than compound 1 and was optimized using structural information to achieve improved antibacterial activity against wild-type E. coli. These results show